These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22585991)

  • 1. Drug interactions: the importance of looking inside cancer cells.
    Clark JW
    Cancer Discov; 2012 Mar; 2(3):208-10. PubMed ID: 22585991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
    Frese KK; Neesse A; Cook N; Bapiro TE; Lolkema MP; Jodrell DI; Tuveson DA
    Cancer Discov; 2012 Mar; 2(3):260-269. PubMed ID: 22585996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
    Michl P
    Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
    [No Abstract]   [Full Text] [Related]  

  • 4. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
    Passacantilli I; Panzeri V; Terracciano F; Delle Fave G; Sette C; Capurso G
    Oncol Rep; 2018 Apr; 39(4):1984-1990. PubMed ID: 29393478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
    Awasthi N; Zhang C; Schwarz AM; Hinz S; Wang C; Williams NS; Schwarz MA; Schwarz RE
    Carcinogenesis; 2013 Oct; 34(10):2361-9. PubMed ID: 23803690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer.
    Xie CK; Liao CY; Lin HY; Wu YD; Lu FC; Huang XX; Wang ZW; Li G; Lin CF; Hu JF; Chen YH; Li QW; Chen LQ; Chen HX; Chen S
    Mol Cancer; 2024 Sep; 23(1):215. PubMed ID: 39350121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
    Rogers JE; Mizrahi JD; Xiao L; Mohindroo C; Shroff RT; Wolff R; Varadhachary GR; Javle MM; Overman M; Fogelman DR; Raghav KPS; Pant S; McAllister F
    Cancer Med; 2020 Aug; 9(15):5406-5415. PubMed ID: 32519420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
    Kaneko T; Sugimori K; Tozuka Y; Fukushima T; Okada K; Oka H; Okazaki H; Maeda S
    Clin J Gastroenterol; 2019 Oct; 12(5):484-489. PubMed ID: 30993653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
    Meng H; Wang M; Liu H; Liu X; Situ A; Wu B; Ji Z; Chang CH; Nel AE
    ACS Nano; 2015; 9(4):3540-57. PubMed ID: 25776964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.
    Blomstrand H; Green H; Fredrikson M; Gränsmark E; Björnsson B; Elander NO
    BMC Cancer; 2020 Oct; 20(1):950. PubMed ID: 33008332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
    Hingorani SR; Zheng L; Bullock AJ; Seery TE; Harris WP; Sigal DS; Braiteh F; Ritch PS; Zalupski MM; Bahary N; Oberstein PE; Wang-Gillam A; Wu W; Chondros D; Jiang P; Khelifa S; Pu J; Aldrich C; Hendifar AE
    J Clin Oncol; 2018 Feb; 36(4):359-366. PubMed ID: 29232172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
    Prager GW; Oehler L; Gerger A; Mlineritsch B; Andel J; Petzer A; Wilthoner K; Sliwa T; Pichler P; Winder T; Heibl S; Gruenberger B; Laengle F; Hubmann E; Korger M; Pecherstorfer M; Djanani A; Neumann HJ; Philipp-Abbrederis K; Wöll E; Trondl R; Arnold-Schrauf C; Eisterer W
    Eur J Cancer; 2021 Jan; 143():101-112. PubMed ID: 33296830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer.
    Sarantis P; Bokas A; Papadimitropoulou A; Koustas E; Theocharis S; Papakotoulas P; Schizas D; Papalampros A; Felekouras E; Papavassiliou AG; Karamouzis MV
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34208987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
    Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
    Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.
    Oliverius M; Flasarova D; Mohelnikova-Duchonova B; Ehrlichova M; Hlavac V; Kocik M; Strouhal O; Dvorak P; Ojima I; Soucek P
    Mutagenesis; 2019 Dec; 34(5-6):403-411. PubMed ID: 31375828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
    Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
    Heinemann V; Reni M; Ychou M; Richel DJ; Macarulla T; Ducreux M
    Cancer Treat Rev; 2014 Feb; 40(1):118-28. PubMed ID: 23849556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
    Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
    Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.